Vav proteins are phosphorylation-dependent guanine nucleotide exchange factors (GEFs) that catalyze the activation of members of the Rho family of guanosine triphosphatases (GTPases). The current regulatory model holds that the nonphosphorylated, catalytically inactive state of these GEFs is maintained by intramolecular interactions among the amino-terminal domains and the central catalytic core, which block the binding of Vav proteins to GTPases. We showed that this autoinhibition is mechanistically more complex, also involving the bivalent association of the carboxyl-terminal Src homology 3 (SH3) region of Vav with its catalytic and pleckstrin homology (PH) domains. Such interactions occurred through prolinerich region-independent mechanisms. Full release from this double-locked state required synergistic weakening effects from multiple phosphorylated tyrosine residues, thus providing an optimized system to generate gradients of Vav GEF activity depending on upstream signaling inputs. This mechanism is shared by mammalian and Drosophila melanogaster Vav proteins, suggesting that it may be a common regulatory feature for this protein family.
INTRODUCTION
The Vav family is a group of tyrosine phosphorylation-dependent guanine nucleotide exchange factors (GEFs) that activate members of the Rac and Rho families of guanosine triphosphatases (GTPases) downstream of protein tyrosine kinases (1) (2) (3) (4) (5) (6) (7) (8) . This family consists of single proteins in invertebrates and three members in most vertebrate species (Vav1, Vav2, and Vav3) (4, 5) . Genetic analyses have demonstrated that these proteins play critical functions in many biological responses, including lymphopoiesis (3, 9) , osteogenesis (10), cardiovascular homeostasis (11) (12) (13) (14) , neuronal-related processes (13, (15) (16) (17) , and tissue rhythmic behaviors in nematodes (18) . Vav family proteins are also involved in human pathologies, such as cancer (19) (20) (21) (22) (23) (24) , metabolicrelated diseases (25) , multiple sclerosis (26) , immune-related deficiencies (26) , and the life cycle of pathogens inside eukaryotic host cells (4) .
Vav proteins are characterized by the presence of a complex array of structural domains (Fig. 1A ). These include a calponin homology (CH) domain and an acidic (Ac) region with three regulatory phosphorylation sites (Tyr 142 , Tyr 160 , and Tyr 174 in the case of Vav1) (27) ; central Dbl homology (DH), pleckstrin homology (PH), and C1 type zinc finger (ZF) domains that fold together to form the active catalytic core (7, (28) (29) (30) ; and a C-terminal arrangement of either Src homology 2 (SH2)-SH3 domains (in invertebrates) or SH3-SH2-SH3 domains (in organisms from prochordates to mammals) (5) . The noncatalytic domains exert pleiotropic roles during signal transduction, which contribute to the intramolecular regulation of Vav proteins, the phosphorylation step, and the engagement of GTPase-independent routes (4). These roles are not mutually exclusive because, for example, the CH region inhibits the catalytic activity of Vav in cis (6, 7, 31 ) and, at the same time, plays effector roles that favor the engagement of Ca 2+ -dependent routes that stimulate nuclear factor of activated T cells (NFAT) (32) , a transcriptional factor involved in lymphocyte proliferation (33) . Similarly, the most C-terminal SH3 domain (referred to hereafter as the CSH3 domain) interacts with proline-rich region (PRR)-containing proteins that favor downstream signaling and, in the case of T lymphocytes, the optimal phosphorylation of Vav proteins in response to activation of the T cell receptor (TCR) (4, 5, 34) .
According to the current regulatory model, nonphosphorylated Vav proteins are catalytically inactive because of the physical occlusion of the GTPase-binding site in the DH domain by the CH-Ac region ( fig. S1A ) (31) . This closed, autoinhibited structure is stabilized by interactions between the Tyr 174 hydroxyl group and the GTPase-binding region of the DH domain, as well as by interdomain contacts between the CH domain and the DH-PH region (fig. S1B) (31) . Upon cell stimulation, the phosphorylation of the three tyrosines located in the Ac region eliminates these inhibitory interactions, which leads to exposure of the catalytic site, binding to the GTPase, and the ensuing catalytic step (fig. S1A) (31) . Consistent with this model, mutations that disrupt such an autoinhibitory structure result in proteins with constitutive, phosphorylation-independent catalytic activity both in vitro and in cells ( fig. S1A) (6, 7, 27, 28, 31) .
It is still uncertain, however, whether this model alone can fully explain the regulation of Vav activity. For example, we observed that Vav1 Y174F , a mutant protein that lacks the main inhibitory tyrosine residue, still requires tyrosine phosphorylation to become catalytically active in vitro (27) . We also reported that the compound mutation of the three tyrosine residues of the Ac region does not recapitulate the activation effect derived from the deletion of the CH domain in Vav proteins (27, 28) , thus suggesting that the autoinhibited structure can be stabilized by additional interactions outside the Ac region. Finally, Vav proteins have additional phosphorylatable residues outside of the Ac region (27) , suggesting that further phosphorylation-dependent steps may contribute to fine-tune the regulation of these proteins during signal transduction. Consistent with these ideas, we report here that optimal autoinhibition of Vav proteins requires cooperative intramolecular interactions mediated by the CSH3 domain. This mechanism provides a multilayered safety control system to avoid spurious 1 Centro de Investigación del Cáncer, Campus Unamuno, E37007 Salamanca, Spain. 2 Instituto de Biología Molecular y Celular del Cáncer, Consejo Superior de Investigaciones Científicas (CSIC)-University of Salamanca, Campus Unamuno, E37007 Salamanca, Spain. activation of these proteins by signaling noise and, at the same time, a potential way to modulate the signaling competence of Vav proteins depending on either the strength or the duration of extracellular stimuli.
RESULTS

The CSH3 domain participates in the inhibition of Vav family proteins
During the course of experiments aimed at establishing the regulatory role of the C terminus of Vav1, we generated a 10-amino acid-long deletion mutant that disrupted the folding of the Vav1 CSH3 domain (Vav1 D835-845 ; Fig. 1A ). Given the important role of Vav1 in lymphocyte signaling (3) (4) (5) 9) , we first tested the biological activity of this mutant in Jurkat cells (a human CD4 + T cell leukemia cell line), and we used as readouts the Vav1-dependent activation of c-Jun N-terminal kinase (JNK), F-actin polymerization, and NFAT. JNK and F-actin are direct downstream elements of the Vav1-Rac1 pathway and, therefore, were used as surrogate readouts for Vav1 catalytic activity in cells (Fig. 1B) . In contrast, NFAT requires multiple signaling inputs for its activation, including signals dependent on the Vav1 CH domain, phospholipase C-g-dependent Ca 2+ signaling, and synergistic crosstalk with other TCR-activated pathways (Fig. 1B) (9, 32, 35 displays phosphorylation-independent GEF activity because of the elimination of the inhibitory N-terminal domains (Fig. 1A ) (6, 7, 28) ; however, it cannot stimulate NFAT because of the lack of the N-terminal CH domain (Fig. 1B) (28, 32) . As mentioned earlier, the Vav1 Y174F mutant exhibits increased activity in some assays; however, unlike Vav1
D1-186
, it still requires phosphorylation steps to become fully activated in vitro and in cells (27) .
Because previous data demonstrated that the interaction of the Vav1 CSH3 domain with PRR-binding proteins was required for the biological activity of Vav1 in most cell types (28, 34, 36, 37) , we expected that the CSH3-deficient Vav1 D835-845 mutant would exhibit less activity than that of its wild-type counterpart; however, we unexpectedly found that Vav1 D835-845 was as hyperactive as Vav1 D1-186 in experiments measuring the activation of JNK (Fig. 1 , C to F) and F-actin polymerization (Fig. 1G ). This increased activity was quite similar in nonstimulated and TCR-stimulated Jurkat cells (Fig. 1, C to F (28, 32) , also showed enhanced activity when tested in NFAT activity assays (Fig. 1 , H and I); however, this biological response still required the engagement of the TCR to achieve maximal stimulation (Fig. 1, H and I). We observed similar results in experiments in which chicken DT40 B cells were transiently transfected with plasmid encoding Vav1 D835-845 (Fig. 1 , H and I), which indicated that the increased activity of this C-terminally truncated Vav1 protein was conserved in both T cell and B cell lines.
Vav1 D835-845 also showed higher biological activity than that of Vav1 WT in assays of JNK activity and F-actin polymerization in nonhematopoietic COS1 cells; however, unlike in lymphocytes, the activity of Vav1 D835-845 was substantially reduced compared to that of Vav1 D1-186 (Fig. 2 , A and B, and fig. S2A ) and Vav1
Y3xF ( fig. S2A ), a mutant Vav1 in which the three inhibitory tyrosine residues of the Ac region are mutated to phenylalanines (Fig. 1A) (27) . Furthermore, unlike the conventional Vav1 D1-186 and Vav1
Y3xF mutant proteins (6, 27, 28) , Vav1 D835-845 did not exhibit oncogenic activity when tested in focus formation assays (Fig. 2C) . The reduced activity of Vav1 D835-845 in COS1 and NIH3T3 cells was probably a result of the loss of CSH3-dependent effector functions, because the Vav1
Y3xF protein also lost its transforming activity (27, 28) when it lacked the C-terminal amino acid residues 835 to 845 (Fig. 2C ). This deletion also induced the constitutive activation of Vav2, Vav3 (Fig. 2, D and E), and Drosophila Vav (Fig. 2, A and B) , indicating that the inhibitory role exerted by this domain may be common to all Vav family members. Despite this, the C-terminal truncation did not change the specific signaling output induced by each Vav family member in cells. For example, we observed that Vav2 D860-868 stimulated NFAT in B cells, but not in T cells, a cell type specificity also shared by Vav2
WT (fig. S2 , B and C) (38) . Together, these results suggest that the CSH3 domains of Vav family members exert a hitherto unknown inhibitory role that may have arisen very early on in the evolutionary history of this GEF subgroup. Moreover, these results suggest that the relative contribution of the negative and positive roles of the CSH3 domain to the biological activity of these proteins is highly dependent on the cell type and biological response involved.
The CSH3 domain inhibits the catalytic activity of Vav proteins
To investigate whether the enhanced biological activity of CSH3-deficient Vav proteins was a consequence of increased catalytic activity, we isolated hexahistidine (6xHis)-tagged variants of Vav1 D841-847 from baculovirus-infected Sf 9 insect cells (Fig. 3A ) and subsequently tested them in vitro in guanosine diphosphate-guanosine 5′-triphosphate (GDP-GTP) exchange assays. As a negative control, we used a 6xHis-Vav3 protein fragment that contains only the DH-PH region (Vav3 DH-PH ; Fig. 3A ). We showed previously that this protein is catalytically inactive because of the absence of the ZF region (7) . As a positive control, we used the 6xHis-DH-PH region of a RhoA-and Cdc42-specific GEF (human Dbs), which was provided by the commercial kit used to assay GDP-GTP exchange. With this approach, we observed that 6xHis-Vav1
WT was catalytically inactive on all of the GTPases tested (Fig. 3 , B to D); however, as expected (8, 27, 28) , 6xHis-Vav1
WT became catalytically active upon in vitro phosphorylation by the protein tyrosine kinase Lck (Fig. 3, E and F) . In contrast, 6xHis-Vav1 D835-845 exhibited phosphorylation-independent GDP-GTP exchange activity on both Rac1 (Fig. 3B) and RhoA (Fig. 3C ). This activity was proportional to the amount of input protein used in the assays (Fig. 3 , B and C). Vav1 D835-845 did not elicit any detectable nucleotide exchange activity on Cdc42 (Fig. 3D ), as was previously described for other Vav1 variants (8) . Dbs showed the opposite catalytic specificity, being primarily active on RhoA (Fig. 3C) and Cdc42 (Fig. 3D) , whereas it displayed much lower activity on Rac1 (Fig. 3A) .
Parallel experiments indicated that 6xHis-Vav3 D841-847 had constitutive, phosphorylation-independent exchange activity toward Rac1 (Fig. 3G ) and, to a lesser extent, RhoA (Fig. 3H ). Similar to its Vav1 mutant counterpart, 6xHis-Vav3 D841-847 did not show activity on Cdc42 (Fig.  3I) . The catalytic activity of this mutant protein was comparable to that shown by the previously described constitutively active Vav3 D1-144 protein (Fig. 3G) (7) . Confirming the specificity of these reactions, we did not observe any exchange activity when the purified 6xHis-Vav3 DH-PH region was tested (Fig. 3G) mutant protein (Fig. 3 , K and L). As expected, the full-length Vav1 and DmVav proteins were inactive in these assays (Fig. 3 , K and L). These results indicate that the CSH3 domain contributes to the regulation of both the catalytic and biological activities of Vav family proteins, possibly through an inhibitory intramolecular mechanism similar to that exerted by the N-terminal CH domain and Ac region.
The CSH3 domain inhibits Vav1 activity in cis
To elucidate the inhibitory role of the CSH3 domain, we first investigated whether it could be mediated by a canonical interaction with PRRs.
Arguing against this possibility, we observed that the inactivation of the PRR-binding site of the Vav1 CSH3 domain (through the introduction of the P833L mutation) did not induce the activation of full-length Vav1 (Fig. 4 , A and B). This result was consistent with previous experimental data (4, 5, 34) . These observations led us to investigate whether the CSH3 domain inhibited Vav1 through a PRR-independent mechanism in cis. To this end, we performed GST-based pull-down experiments to detect possible interactions of the wild-type (GST-CSH3 WT ) and the P833L mutant (GST-CSH3 P833L ) versions of the Vav1 CSH3 domain, with Vav1 proteins ectopically expressed in COS1 cells. Because we surmised that access to the putative CSH3-binding site of Vav1
WT could be blocked by the interaction of its own CSH3 (Fig. 4C) , we decided to include in these experiments the mutants Vav1 D835-845 and Vav1
D1-186
. On the basis of earlier results (Figs. 1 to 3) , we expected that the CSH3-binding site of Vav1 D835-845 would be fully exposed and, therefore, that this mutant would serve as a good positive control for these experiments (Fig. 4C) . On the other hand, the use of the Vav1 D1-186 mutant enabled us to check whether the strength of the intramolecular CSH3-Vav1 interaction could be influenced by the previously described CH domain-and Ac region-dependent conformational changes associated with the catalytic activation of Vav proteins (29) (30) (31) .
We found that GST-CSH3 WT physically interacted with Vav1 (Fig. 4D) , indicating that the truncation of the CSH3 domain was required to expose its intramolecular binding site. The GST-CSH3 P833L protein consistently showed better interactions with Vav1 D835-845 than did the GST-CSH3 WT bait (Fig. 4D) , thus corroborating the idea that this intramolecular inhibitory mechanism is mediated by a noncanonical, PRR-independent mechanism. Furthermore, the GST-CSH3 P833L bait also showed weaker, but reproducible, binding to Vav1
WT and, to a larger extent, to Vav1 D1-186 (Fig. 4D) . All of these interactions were specific because the nonchimeric GST protein did not interact with any of the Vav1 proteins used in these experiments (Fig. 4D) . These interactions were also highly selective, as demonstrated by the lack of efficient binding of the GST-CSH3 P833L bait to other C-terminally truncated Vav family proteins (Fig. 4E) . Together, these results suggest that the stability of the intramolecular CSH3-Vav1 interaction is stronger when Vav1 is in the nonactive state, is partially destabilized upon the release of the inhibitory N-terminal regions (Vav1 D1-186 ), and is totally disrupted when the CSH3 is truncated (Vav1 D835-845 ). Furthermore, these results suggest that the binding of PRR-containing proteins to the canonical PRRbinding site of CSH3 might indirectly disrupt the interaction between CSH3 and Vav1. 
The CSH3 domain binds to the DH-PH region of Vav1
The interaction of the GST-CSH3 P833L bait with both Vav1 D1-186 and Vav1
D835-845 that we observed in the earlier experiments indicated that the internal CSH3-binding site must lie outside the CH-Ac and CSH3 regions. The use of additional mutant proteins also excluded the possibility that the binding site could be located in the PRR-NSH3 region of Vav1 ( fig. S3 ), thus suggesting that the interaction was likely to take place within the catalytic DH-PH-ZF cassette. To test this possibility, we investigated the interaction of the GST-CSH3 P833L bait with different combinations of the domains present in that cassette in pull-down experiments (Fig. 4F ).
To facilitate these experiments, we expressed these regions in COS1 cells as fusions with enhanced green fluorescent protein (EGFP). We observed that GST-CSH3 P833L interacted with EGFPs containing the DH (EGFP-DH-PH-ZF, EGFP-DH-NPH, and EGFP-DH) and PH (EGFP-DH-PH-ZF and EGFP-PH) domains of Vav1 (Fig. 4 , G and H, and fig. S4A); however, it did not associate with the isolated ZF domain (Fig. 4G) or the a6 helix of the DH domain ( fig. S4A) . Furthermore, the ZF domain seemed to constrain the interaction of the Vav1 CSH3 domain with its targets because the EGFP-DH-NPH and EGFP-PH constructs showed better binding to the GST-CSH3 P833L bait in these experiments than did the EGFP-DH-PH-ZF construct ( Fig. 4G and fig. S4A ). Furthermore, the DH region showed a better association to the bait when the DH region was attached to the NPH fragment (Fig. 4H ). These results suggest that the CSH3 domain probably has two independent docking sites within the DH-a6-PH region and, in addition, that the stability of such interactions may be influenced by conformational fluctuations imposed by the intervening a6 helix and the adjacent ZF region.
Additional pull-down experiments indicated that the ectopically expressed EGFP-Vav1 DH-PH-ZF cassette interacted more efficiently with GST-CSH3 P833L than with other known interacting partners, such as the 
downstream GTPases and the inhibitory N-terminal CH region (fig. S4B).
Confirming that the interaction between the CSH3 domain and the DH-PH-ZF region of Vav1 did not require the participation of other proteins present in the COS1 cell lysates used in the pull-down experiments, we found with purified proteins (Fig. 4I ) and surface plasmon resonance techniques that a bacterially expressed Vav1 DH-PH-ZF region fused to the maltosebinding protein (MBP) associated with the filter-immobilized GST-CSH3 WT bait (Fig. 4J) . As a negative control, MBP fused to b-galactosidase (Fig. 4I) showed no detectable interaction with the GST-CSH3
WT bait (Fig. 4J ). To further support these observations, we performed electron microscopy (EM) experiments to obtain a low-resolution image of the unphosphorylated 6xHis-Vav1 D1-144 mutant. This protein lacks the inhibitory CH domain and, similar to Vav1
D1-186
, shows constitutive, phosphorylationindependent activity (7, 28) . Although EM analysis does not yield data at atomic resolution, it can provide useful information about the shape and volume of proteins under analysis, as well as the stereo-spatial distribution of structural domains within these volumes. The analysis of purified fractions of 6xHis-Vav1 D1-144 ( fig. S5A ) revealed that 6xHis-Vav1 D1-144 displayed a homogeneous structure characterized by the presence of a bulky area (referred to as the "head") and an elongated extension (designated as the "tail") ( fig. S5B ). Images derived from different rotated views of the molecule along its axis were collected ( fig. S5C ) and processed to generate an average three-dimensional (3D) reconstruction with an overall resolution of ≈32.5 Å (fig. S5D ).
We next used in silico docking methods to define the stereo-spatial distribution of the DH-PH-ZF and SH3-SH2-SH3 regions within the EM-generated volume. Because the structure of the Vav1 C terminus is unknown, we used the available crystal structure of Grb2 (40), an adaptor protein with a Vav1-like arrangement of SH2 and SH3 domains, to model docking. These methods assigned the catalytic DH-PH-ZF core to the head region of 6xHis-Vav1 D1-144 ( fig. S5D ). Although the limited resolution of the EM structure prevented us from performing an unbiased modeling, the flat shape of this area and its connectivity to the C-terminal tail favored certain orientations of the DH-PH-ZF cassette ( fig. S5D ). The SH2 domain and one of the two SH3 domains of Grb2 could be fitted within the tail of 6xHis-Vav1 D1-144 without any deviation from their localization within the crystal structure of Grb2 ( fig. S5D ). In contrast, the second SH3 region of Grb2 required a substantial clockwise rotation toward the head region to be fully accommodated within the density of 6xHis-Vav1 D1-144 ( fig. S5D ). Such movement is structurally possible because previous results have shown that Grb2 adopts multiple conformational states because of the flexibility of its interdomain linker regions (41) . Consistent with our biochemical data, this rotation placed the SH3 domain in close proximity to the PH domain and the C-terminal side of the DH domain, including the a6 helix, of Vav1 ( fig. S5D ). This location is also in the vicinity of the docking site of the CH domain and part of the Ac region when Vav1 is in the nonphosphorylated, inactive conformation (31). However, unlike the case of the CH region, the presence of the CSH3 domain in that location should not interfere with the GEF activity of Vav1, because we previously showed that the 6xHis-tagged Vav1 D1-144 and Vav3
D1-144
oncoproteins have phosphorylation-independent GEF activity in vitro (7, 28) .
The DH domain a6 helix stabilizes the inhibitory CSH3-Vav1 interaction
To gain further information about this previously uncharacterized regulatory mechanism, we first focused our attention on the DH domain a6 helix (Fig. 5A ). This region was of interest because its integrity was clearly important for the interaction between the CSH3 domain and the DH-PH region that we detected in pull-down experiments (Fig. 4 , G and H, and fig. S4A ). Furthermore, the DH a6 helix undergoes large topological changes during the activation step of Vav proteins ( fig. S6 ) (29) (30) (31) . We hypothesized that if residues of the a6 helix were important for the stability of the intramolecular CSH3-Vav1 interaction, then their mutation in Vav1 D835-845 would result in the loss of interaction with the GST-CSH3 fusion protein in pull-down experiments.
We chose the residues to be mutated based on evolutionary conservation criteria, their localization in areas undergoing topological changes between the inactive and active catalytic states of Vav1 ( fig. S6) , and their being present in all of the EGFP-Vav1 fragments that we found could bind to the CSH3 region (Fig. 5A) . As a control, we mutated two less-conserved residues (Thr  384 and Leu   388 ), which are located further downstream in the DH domain a6 helix (Fig. 5A) . We mutated the chosen residues to alanines to avoid major conformational changes (42 (Fig. 5B ). We next analyzed the biological activity of the Vav1 D376A mutant to confirm its involvement in the CSH3-dependent inhibitory mechanism. We assumed that if this residue contributed to Vav1 autoinhibition, its mutation would release the CSH3 domain from its binding site and, therefore, would result in the enhanced activation of the full-length protein in cells. If so, such data could also contribute to ruling out the possibility that the disruption of the interaction between GST-CSH3 P833L and Vav1
D835-845
that we observed earlier (Fig. 5B ) might be because of spurious effects of the D376A mutation in the overall Vav1 structure. Confirming our pull-down data, we observed that Vav1 D376A , but not Vav1
K374A
, displayed increased biological activity compared to that of Vav1 WT in both JNK and NFAT assays (Fig. 5, C and D) . Similarly, we observed that the D376A mutation led to an increase in the binding of the full-length Vav1 protein to the target GTPase Rac1 (Fig. 5E ). These results indicate that specific residues within the C-terminal a6 helix of the DH domain of Vav1, a region that undergoes a large rotation and displacement during Vav1 activation ( fig. S6 ), contribute to the stabilization of the interaction between the CSH3 domain and the central domains of Vav1. However, this stabilization is not mediated by direct interactions because the a6 helix of Vav1 alone did not bind to the CSH3 domain ( fig. S4A ).
Residues at the RT loop and the C-terminal end of the CSH3 domain are involved in the inhibition of Vav1
To identify the CSH3 residues involved in the intramolecular CSH3-Vav1 interaction, we assumed that their single or compound mutation into alanine residues would release this interaction and, therefore, make the intramolecular binding site of the CSH3 domain accessible to the GST-CSH3 bait proteins used in our pull-down experiments. A first round of pulldown experiments ruled out the individual involvement of 23 surfaceexposed CSH3 residues ( fig. S7, A and B) , although the point mutation , and Asp 840 around those sites, which are referred to as DFCmut, DFC-Rmut, and YVEEDmut, respectively (Fig. 6A) , revealed that mutations affecting the DFC-R and YVEED patches did promote increased binding of the respective mutant proteins to the GST-CSH3 P833L bait (Fig. 6B, left panels) . When taking into consideration the abundance of each mutant protein in the COS1 cell lysates used in these pull-down experiments (Fig. 6B, bottom left panel) , we observed that the DFCmut had a slightly stronger effect in favoring the opening of the full-length Vav1 protein than did the YVEEDmut (Fig. 6B, top panel, compare lanes 3 and 5) . The combined mutation of the DFC-R patch and the YVEED region did not further increase the extent of binding of the mutant proteins to the bait (Fig. 6B, top panel on the left, compare lanes 4 and 6) . These results indicate that these two sites of the CSH3 domain contribute to the formation of the autoinhibited state of the full-length Vav1 protein.
Confirming the involvement of the DH domain a6 helix in these interactions, we observed that the compound Vav1 D376A+DFC-Rmut mutant protein interacted very poorly with the GST-CSH3 P833L fusion protein (Fig. 6B , right panels). Experiments with transfected Jurkat cells indicated that the Vav1 DFC-R+YVEEDmut protein induced the TCR-independent stimulation of JNK activity (Fig. 6, C and D) and F-actin polymerization (Fig. 6E) , similarly to Vav1 D835-845 and Vav1
D376A
. The Vav1 DFC-R+YVEEDmut protein also enhanced basal NFAT activity, a response that was further increased upon TCR stimulation ( fig. S8, A and B) . The combined DFC-R+YVEED and D376A mutations did not increase the biological activity already displayed by the Vav1 DFC-R+YVEEDmut and Vav1 D376A proteins (Fig. 6, C and D, and fig. S8 , A and B), indicating that all of those residues functioned redundantly in the regulation of Vav1 activity.
We obtained similar results when we tested these proteins in COS1 cells with JNK activity assays ( fig. S8, C and D) and GST-Rac1 YVEEDmut proteins in cells when compared to that shown by Vav1 DFC-R+YVEEDmut (Fig. 6, F and G) . However, we found that Vav1
DFC-Rmut showed increased basal activity compared to that of Vav1 WT (Fig. 6 , F and G), indicating that the DFC-R motif contributes more substantially to the stabilization of the autoinhibited state of Vav1 than does the YVEED motif, when tested in cells. Ruling out the possibility that the activation of the Vav1 D376A+DFC-Rmut mutant might be a result of the deleterious effects of the mutations in the overall folding of the CSH3 domain, we demonstrated that a Vav1 CSH3 domain that had mutations in the DFC-R, YVEED, and DFC-R+YVEED regions could still efficiently bind to hnRNPK (heterogeneous ribonucleoprotein K), a protein that interacts with the Vav1 CSH3 domain through a canonical, PRR-based interaction ( fig. S8F) (43, 44) . As a control, we found that the interaction between hnRNPK and the CSH3 domain was abolished when the PRR-binding site of CSH3 was inactivated by the incorporation of the P833L mutation ( fig. S8F) (43, 44) . The large spatial distribution of the Vav1 CSH3 domain residues involved in the inhibition of the full-length protein led us to investigate the possibility that the DFC and YVEED motifs might be involved in the recognition of independent regions of the catalytic DH-PH-ZF core, an idea that is also consistent with our earlier observations that indicate that the Vav1 CSH3 domain binds to both the isolated DH and PH regions of Vav1 (Fig. 4,  G and H, and fig. S4A ). To evaluate this possibility, we investigated the binding of the GST-CSH3 , GST-CSH3
P833L+YVEEDmut
, and GST-CSH3 DFC-Rmut+P833L+YVEEDmut fusion proteins to all of the domains present in the Vav1 catalytic core (Fig. 4F) . We observed that mutation of the DFC-R region eliminated the interaction between the GST fusion protein and the Vav1 DH-NPH region, but not the Vav1 PH region (Fig. 6H) . Conversely, mutation of the YVEED region abolished the interaction between the bait and the Vav1 PH region, but not the Vav1 DH-NPH region (Fig. 6H) . As was expected from our previous results, compound mutations of the DFC-R and YVEED regions eliminated the interaction between GST-CSH3 P833L and all of the ectopic proteins, including EGFP fused to the entire DH-PH-ZF cassette (Fig. 6H) . These results indicate that the Vav1 CSH3 domain uses residues present in the RT loop (DFC-R motif ) and its C-terminal end (YVEED motif) to interact with the DH and PH regions, respectively (Fig. 6A ).
Multiple phosphorylation sites are involved in the activation of Vav1 in cells
Given the close connection between Vav1 and tyrosine kinase-regulated signaling pathways (5, 45), we decided to investigate whether the loss of the CSH3-dependent inhibitory interaction could be mediated by tyrosine phosphorylation-dependent events. In addition to the previously known phosphorylation sites at Tyr (table S1) . Tyr 541 and Tyr 544 are located in the ZF domain of Vav1, and they establish bonds with residues present in the PH-ZF region ( fig. S6B) (29, 30) , whereas Tyr 836 is located in the YVEED motif of the CSH3 domain (Fig. 6A) .
To confirm the proteomics data with independent techniques, we generated rabbit polyclonal phospho-specific antibodies against each of these residues and, in addition, to two of the previously known phosphorylation sites: Tyr 142 and Tyr
160
. A phospho-specific antibody against the key regulatory residue Tyr 174 was reported previously (27) . We demonstrated the specificities of these antibodies through the detection of the phosphorylation of each of residues of interest in Vav1 WT , but not in the appropriate phospho-site mutant proteins, in EGF-stimulated COS1 cells ( fig. S9) (Fig. 7A ). We mutated these previously uncharacterized phospho-sites into either phenylalanine or glutamate residues in full-length Vav1 to assess their contributions to the activation of Vav1 in cells. In addition, we modified these residues in the context of the Vav1 Y174F mutant protein to detect potential synergisms with the phospho-sites involved in the release of the inhibitory N-terminal domains. When we tested these mutants in JNK assays, we found that the effects of the mutations were highly contingent upon both the stimulation state and the type of Vav1 protein used. In unstimulated Jurkat cells, the Y541F, Y544F, Y836F, and Y836E Vav1 point mutants displayed biological activities slightly greater than that of Vav1 WT , whereas the Y836F and Y836E mutants had activities that were greater than those shown by both Vav1 WT and Vav1 Y174F (Fig. 7 , B and C). The Vav1 Y541E and Vav1 Y544E mutant proteins exhibited activities similar to that of Vav1 WT (Fig. 7 , B and C), indicating that the single mutation of each of those two residues did not substantially affect the basal activities of these proteins. However, in Jurkat cells stimulated with anti-CD3 antibody, the phospho-site mutants were unexpectedly less active than were the Vav1 WT and Vav1 Y174F proteins (Fig. 7 , B and C), indicating that the phospho-site mutants had become insensitive to upstream stimulation. A similar defect was seen in the case of Vav1 P833L (Fig. 4A) , which was probably a result of the known requirement of the canonical PRR-binding site of the Vav1 CSH3 domain for the optimal phosphorylation of Vav1 in lymphoid cells (34) . A similar explanation can be used in the case of the Y833F and Y836E mutations because these residues are located in the vicinity of the PRR-binding site. Consistent with this interpretation, the Vav1
YVEEDmut protein (which contains the Y836A mutation and can bind to PRR-containing proteins) showed activity very similar to that of Vav1 WT in TCR-stimulated cells (Fig. 6, C and F) . In this functional context, it is possible that the lack of responsiveness of the Vav1 ZF phospho-site mutants to TCR stimulation could be caused by conformational changes that, by restricting the accessibility of the PRR-binding site of the CSH3 domain to other signaling proteins, could inhibit phosphorylation of the protein. Consistent with this idea, we found that the concurrent mutation of Tyr 174 restored the TCR responsiveness of the Y544E mutant protein (Fig. 7, B and C) . Furthermore, this mutation synergized with the rest of the phospho-site mutations, which led to the generation of constitutively active proteins in all cases (Fig. 7, B and C) . The most marked effect was observed in the case of the compound Y174F,Y836E mutant protein, which displayed biological activities that were similar to those of the Vav1 D1-186 and Vav1
D835-845
mutants (compare Figs. 1C and 7B ), but were increased compared to those of the Vav1 Y174F or Vav1 Y3xF mutants (Fig. 7 , B and C). Although the Vav1 Y174F+Y544E protein was not constitutively active, it enhanced the activation of JNK compared to that of Vav1 WT under both unstimulated and stimulated conditions (Fig. 7, B and C) . These results indicate that the full activation of Vav1 under physiological conditions requires the synergistic effect of multiple phosphorylation sites located in the Ac, ZF, and, to a much larger extent, the CSH3 regions. In addition, these results suggest that Vav1 can adopt different conformational or functional states depending on the specific tyrosine residues that are phosphorylated at any given time.
To establish a connection between the constitutive activation of the phospho-site mutant proteins and the release of the intramolecular CSH3-Vav1 interaction, we evaluated their interactions with the GST-CSH3 P833L bait in pull-down experiments. Consistent with a partial release of such an inhibitory interaction, we observed that the Y174F mutation promoted the increased binding of full-length Vav1 to the GST-CSH3 P833L bait (Fig. 7D, left panel) . This effect was similar to that caused by truncation of the inhibitory N-terminal domains (Fig. 4D) . The positive effect caused by the Y174F mutation was eliminated when combined with the ZF and CSH3 phospho-site mutations (Fig. 7D, left  panel) , suggesting that each of these residues regulate, depending on their phosphorylation states, the formation of conformational states that affect the stability of the intramolecular CSH3-Vav1 interaction.
Ruling out the possibility that the lack of association between either of the two ZF phospho-site mutant proteins and the GST-CSH3 P833L fusion protein was because of the reestablishment of the intramolecular interaction between the DH-PH-ZF region and the CSH3 domain, we found that these mutations also abolished interactions with the GST-CSH3 P833L bait when introduced into the CSH3-truncated Vav1 D835-845 protein (Fig. 7D, right panel). The binding defects caused by these two phospho-site mutations were not because of spurious effects on the overall structure of Vav1, because the Vav1 Y541F+D835-845 and Vav1 Y544F+D835-845 mutant proteins still retained their ability to interact with GST-Rac1 G15A (Fig. 7E) , contributes to the regulation of Vav1 activity through synergistic crosstalk with phospho-sites localized with the Ac region.
DISCUSSION
We showed that optimal autoinhibition of Vav proteins requires the coordinated interaction of the CH-Ac and CSH3 regions with the central catalytic core (Fig. 7F and fig. S10, point i) . This autoinhibited structure restricts both the catalytic-dependent and catalytic-independent outputs of these proteins, as evidenced by the concurrent stimulation of downstream JNK and NFAT signaling upon disruption of the CSH3-mediated inhibition by mutagenesis techniques. Within this autoinhibited structure, the CH domain and the Ac region seem to be primarily involved in the occlusion of the catalytic site and, to a much lesser extent, in the stabilization of the intramolecular CSH3-Vav1 interaction (Fig. 7F and fig. S10 , points ii and iii). Conversely, the CSH3-mediated interaction does not block the catalytic activity per se; rather, it seems to work as an extra safety latch for the stability of the interaction between the CH and Ac regions and the catalytic core. Consistent with these ideas, we showed that N-terminally deleted proteins were constitutively active despite maintaining the intramolecular CSH3-Vav1 interaction ( fig. S10, point ii) . Furthermore, we showed, through in vitro GDP-GTP exchange assays and assays conducted in TCR-deficient Jurkat cells, that elimination of CSH3-mediated inhibition led to the constitutive activation of Vav proteins even under conditions that did not favor the phosphorylation-dependent release of the CH and Ac regions from the catalytic core ( fig. S10, points iv and v) . These two inhibitory inputs were eliminated by the synergistic effects of several phosphorylated tyrosine residues (Fig. 7F and fig. S10, point vi) , thus providing a simple mechanistic framework to couple the kinase association step with the acquisition of full signaling competence by these proteins during signal transduction. Our mutagenesis experiments revealed that the activation of Vav proteins can be achieved by mutating the regulatory tyrosine residues to either phenylalanine or glutamic acid residues. This suggests that, similarly to the key Tyr 174 residue (27, 31, 46) , the hydroxyl groups of the sites that we identified probably contribute to stabilize the intramolecular inhibitory mechanism reported here. Crystallographic studies will be required to elucidate the multiple interdomain contacts that contribute to the inhibition of the catalytic activities of these proteins.
SH3-mediated autoinhibition events have been described for other Rho GEFs, including intersectin (47, 48) , kalirin (49), Rho GEF4 [also known as ArhGEF4 and adenomatous polyposis coli protein-stimulated GEF (Asef)] (50, 51), and Rho GEF5 [also known as ArhGEF5 and transforming immortalized mammary oncogene product (TIM)] family members (52). The mechanism described here bears some similarity, but not identity, to the SH3-mediated autoinhibition of ArhGEF4 and ArhGEF5 family proteins. Thus, the autoinhibition of ArhGEF4 is mediated by noncanonical interactions of its N-terminal SH3 domain with residues located in the DH-PH region, including the DH a6 helix (50, 51) . However, in this case, the SH3 domain is directly involved in blocking the GTPase-binding site rather than in stabilizing a second inhibitory motif (50, 51) . The activation step is also different because it relies exclusively on the release of the SH3 domain through the interaction of other proteins with an adjacent motif (50) . ArhGEF5 family proteins do have a double inhibitory system consisting of a tyrosine-based inhibitory motif and a CSH3 region (52); however, CSH3-mediated inhibition is based on the recognition of a PRR located outside of the DH-PH cassette (52) . The mechanism by which this interaction is broken during signal transduction is not yet known. These results indicate that the SH3-regulated Rho GEF subfamilies use rather idiosyncratic mechanisms to transit in and out of the autoinhibited state.
The autoinhibitory and phosphorylation-dependent activation mechanisms described here may provide additional regulatory layers for the spatiotemporal control of Vav proteins during cell signaling. For example, the requirement of multiple phosphorylation sites for the activation step offers an obvious buffering mechanism against spurious activation events derived from the stochastic phosphorylation of Vav proteins at single sites. Such background phosphorylation "noise" does exist in cells, as evidenced by the basal amount of Vav phosphorylation that we detected under unstimulated conditions. The intensity, diversity, or both of signaling downstream of Vav may also vary depending on the total number and location of the phosphotyrosines engaged at a given time ( fig. S10 , points vi and vii), thus offering a fine-tuning mechanism to adapt such signaling responses to the strength, duration, or type of incoming extracellular stimuli. In the same regulatory context, our observations indicating that mutation of the canonical PRR-binding site of the CSH3 domain enhances the interaction between CSH3 and Vav1 suggest that the association of PRRcontaining proteins with phosphorylated Vav proteins may constrain the return to the autoinhibited state and, as a consequence, prolong Vav signaling under specific stimulation conditions or in specific subcelullar localizations ( fig. S10, point vi) . This may explain the reason for the high functional and structural diversity found so far for the canonical binding partners of Vav family CSH3 domains (4, 5) .
The dependency of an SH3-mediated interaction to maintain an autoinhibited state also has its disadvantages because it could lead to spurious activation events through SH3 displacement mechanisms ( fig.  S10, point viii) . In this context, it is worth noting that the CSH3 domain of Vav is a common signaling target for Nef and M2, two PRR-containing proteins encoded by HIV and g-herpesviruses, respectively (53, 54) . Such a mechanism may be at work in the case of Nef because previous results have shown that it stimulates Vav proteins in a phosphorylation-independent manner (53) . It is also worth noting that our data do not exclude the possibility that, in addition to its direct effect on catalytic activity, the intramolecular localization of the CSH3 domain might regulate the biological activity of Vav family proteins through additional mechanisms. For example, it is feasible that the release of the CSH3 domain during the activation step could favor the surface exposure of other regions of the molecule involved in interactions with other protein partners or cellular structures, such as the plasma membrane. Further work will be needed to understand all of the implications of this previously uncharacterized regulatory mechanism in the dynamic control of Vav proteins during both physiological and pathological signaling conditions.
MATERIALS AND METHODS
Antibodies
Primary antibodies used in this study include a rabbit polyclonal antibody against Vav1 (#301-5) that was generated in house with an MBP fused to the Vav1 DH domain purified from Escherichia coli as an immunogen (28); a rabbit polyclonal antibody against GST (Sigma); and monoclonal antibodies against human CD3 (UCHT1 clone, Merck Millipore), EGFP (Covance), a-tubulin (Santa Cruz Biotechnology), chicken immunoglobulin M (IgM) (SouthernBiotech), and hnRNPK (Merck Millipore). The rabbit polyclonal antibody that is specific for the phosphorylated Tyr 174 residue of Vav1 has been described previously (27) . The other phospho-specific antibodies against Vav1 residues that were used here were generated with tyrosine-phosphorylated peptides as immunogens (Invitrogen custom service). After their generation, the antibodies were positively and negatively selected by chromatographic steps with the appropriate phosphorylated and nonphosphorylated synthetic peptides. Specific recognition of the target phosphorylated sequence was demonstrated by enzyme-linked immunosorbent assay with the appropriate phosphorylated and nonphosphorylated peptides and, in addition, by comparing the signals generated in Western blots with immunoprecipitated wild-type and phospho-site mutant versions of Vav1 from nonstimulated and EGF-stimulated COS1 cells ( fig. S9 ).
Cell lines
Jurkat, DT40, COS1, and NIH3T3 cells were obtained, cultured, and stimulated as described previously (28, 55, 56) .
Expression vectors and in vitro mutagenesis
All constructs used in this work used the mouse versions of mammalian Vav family members. Mammalian expression vectors encoding Vav1
Y3xF (pKES26), EGFP-Vav1 Y3xF (pNM118), Vav1 P833L (pKES42), EGFPVav1 DH-PH-ZF (pNM103), EGFP-Vav1 DH-NPH (pNM109), EGFP-Vav1 PH (pNM111), and EGFP-Vav1 ZF (pNM113) proteins were described previously (27, 28, 57 (27) . A mammalian expression vector encoding EGFP-tagged Vav2 D860-868 (pMB127) was generated by introducing a stop codon in the Vav2 cDNA present in the EGFP-Vav2 WT -encoding vector pAA7 with the primers 5′-CGGTTGGTTT-CCTTCGACGTAGGTGGAAGAGGAAGGCGTCCAG-3′ and 5′-CTGGACGCCTTCCTCTTCCACCTACGTCGAAGGAAACCAACCG-3′ (with the stop codon underlined). To generate the vector encoding EGFPVav3 D841-847 (pMB121), a cDNA fragment was amplified by PCR with the pC-HA-Vav3 plasmid (Addgene) as template and the primers 5′-ATACTCGAGGCCACCATGGAGCCGTGGAAGCAGTGCGCTC-3′ (forward; with the Xho I site underlined) and 5′-CCGGGCGAATTCTTAT-GTGGATGGAAACCAGCCCACCC-3′ (reverse; with the Eco RI site underlined). Upon digestion with Xho I and Eco RI, the Vav3 D841-847 cDNA was ligated into the Bam HI-and Eco RI-linearized plasmid pEGFP-C2 (Clontech). To obtain vectors encoding DmVav WT (pMB122) and DmVav
D781-793
(pMB128), the appropriate cDNA fragment was PCR-amplified from the DmVav-encoding vector pID18 (37) with the primer 5′-ATACTCGAG-GCCACCATGGCCAGCAGCAGTAGCAGCAAC-3′ (forward; with the Eco RI site underlined) in both cases, and either the primer 5′-CCGGGC-GAATTCTCAAAGCTCTTCGCTGGCCAATTTCTG-3′ (reverse; with the Eco RI site underlined) or the primer 5′-CCGGGCGAATTCTCACTTGG-GAAAGTAGCCCACCGTATC-3′ (reverse; with the Eco RI site underlined), respectively, and cloned into pEGFP-C2, as described earlier. The expression vector encoding EGFP-Vav1 DH (pMB49) was generated by introducing a stop codon into the Vav1 cDNA present in pNM109, the vector encoding EGFP-Vav1 DH-NPH, with the primers 5′-CTAGTGAAACA-CACACAGTAGGCTACAGAGAAGGAGAAC-3′ and 5′-GTTCTCC-TTCTCTGTAGCCTACTGTGTGTGTTTCACTAG-3′ (with the stop codon underlined). The expression vector pMB48, which encodes EGFP-Vav1 DH a6 helix, was generated by PCR amplification with pSRM3 as the template and the primers 5′-GGCGAATTCCAGGAGCTAGTGAAACACACACAGGATGCt-3′ (forward; with the Eco RI site underlined) and 5′-AGCTAGGATCCAATATTCAGTTCAGAGACTGGTCCAGGTTC-3′ (reverse; with the Bam HI site underlined , and 6xHis-Vav3 DH-PH were described previously (7, 28, 59) . To express 6xHis-Vav1 D835-845 and 6xHis-Vav3
D841-847
in Sf 9 cells, we mutated the pFastBac plasmids (Life Technologies) containing the full-length Vav1 and Vav3 cDNAs to create a stop codon at the indicated truncation points to generate the pPTK3 and pMB149 vectors, respectively. The bacterial expression vector encoding GST-Vav1 CH (pJZL81) has been described previously (28 To express MBP-Vav1 DH-PH-ZF in bacteria, the Vav1 cDNA encoding these regions, as well as 10 flanking amino acid residues, was subcloned into the pMAL-c plasmid (New England Biolabs) according to standard procedures to generate the final pXRB7 plasmid. All newly generated plasmids were subjected to DNA sequence analysis to rule out the possibility of unwanted mutations.
Biological assays
For , 1 mg per well) was included for 5 min in the last washing step to label the cell nuclei. Samples were analyzed with a Leica TCS SP5 confocal microscope. Images were captured with LAS AF software (version 2.6.0.72266, Leica). Focus formation assays were performed with NIH3T3 cells as previously described (28, 60) . GTPase-linked immunosorbent assays were performed with a commercial kit (Cytoskeleton), as described previously (19, 23) .
Protein detection by Western blotting analysis
Immunoprecipitations and Western blotting analysis were performed according to standard protocols, as described previously (55) .
GDP-GTP exchange assays
Proteins were expressed and purified from baculovirus-infected Sf 9 cells as described previously (7, 59) , and then were gel-quantified with BSA (Sigma) as a concentration standard. The final concentration of 6xHis-tagged proteins (0.25, 0.5, 0.8, or 1 mM) used in the GDP-GTP exchange reactions is indicated in the appropriate figures. Where indicated, 6xHis-Vav1
WT was phosphorylated in vitro with a GST-Lck fusion protein purified from Sf 9 cells, as described previously (7, 59) . As controls, we performed kinase reactions containing either Vav1
WT or the kinase alone. After the kinase reactions were incubated at room temperature for 30 min, aliquots were taken and used in GDP-GTP exchange reactions. The final concentrations of Vav1 and Lck in these assays were 1 and 0.1 mM, respectively. Exchange assays were performed with a commercial kit (RhoGEF exchange assay BK100, Cytoskeleton). In some experiments, we used the human Dbs DH-PH region, which was provided by the exchange assay kit, as a comparative control at the recommended final concentration of 0.8 mM. The 6xHis-tagged GTPases provided by the kit were used in these reactions at a final concentration of 2 mM in all assays. Fluorescence activities were measured every 30 s for 30 min with a Synergy 4 plate reader (BioTek) with Gen5 software (BioTek). For graphical representation, raw data were imported into Excel 12.3.6 (Microsoft), selecting values obtained in 150-s intervals for final representation.
Purification of proteins from E. coli
Isopropyl b-D-1-thiogalactopyranoside-induced GST and MBP proteins in E. coli were purified with glutathione Sepharose (GE Healthcare Life Biosciences) and amylose-coated beads (New England Biolabs), respectively. In the case of MBPs, cultures were induced for 1 hour at 25°C to minimize the generation of truncated versions that ran with a mobility of 37 to 42 kD by SDS-PAGE (containing mostly MBP alone). After washes, GST and MBP proteins were eluted with 10 mM glutathione (Sigma) and 10 mM maltose (Sigma), respectively. Eluted proteins were dialyzed in PBS and used as indicated in the figure legends. In the case of pull-down experiments, GST proteins were kept immobilized on glutathione Sepharose beads. For plasmon resonance determinations, the purified MBP-DH-PH-ZF protein was subjected to a size exclusion chromatography step with a fast protein liquid chromatography apparatus (GE Healthcare Life Biosciences) to eliminate the aforementioned small MBP fragments that copurified with the full-length MBP-DH-PH-ZF chimeric protein. In all cases, protein quantitation was performed with electrophoresed aliquots of samples and gradients of BSA as standards.
GST pull-down experiments
COS1 cells were transfected with 8 mg of each plasmid by the diethylaminoethyldextran/chloroquine method (61) and were cultured for a further 48 hours. Cells were then washed with PBS and disrupted in lysis buffer [20 mM tris-HCl (pH 7.5), 150 mM NaCl, 5 mM MgCl 2 , 0.5% Triton X-100, 5 mM b-glycerophosphate (Sigma), 1 mM dithiothreitol (DTT; USB), and a mixture of protease inhibitors (Cømplete, Roche)]. After eliminating cellular debris by centrifugation at 18,600g for 10 min at 4°C, lysates were incubated for 5 hours at 4°C with~25 mg (in the case of Rac1 G15A and RhoA
G17A
) or 15 mg (for the rest of the assays) of the indicated GST proteins purified from E. coli. Protein complexes were trapped with glutathione Sepharose beads (GE Healthcare Life Biosciences), washed thrice in lysis buffer, resuspended in SDS-PAGE sample buffer, fractionated electrophoretically, and subjected to Western blotting analysis with antibodies against Vav1, EGFP, or hnRNPK. To detect the GST proteins brought down by the beads, blots were stained with a Ponceau solution (Sigma) before the Western blotting step. Alternatively, the samples were analyzed by Western blotting with antibodies against GST after the detection of the pulled down proteins. Aliquots of the same cell lysates that were used for the pull-down experiments were fractionated electrophoretically and subjected to Western blotting analysis to determine the amount of protein in each case. The minimal number of repetitions of an experiment is given in the appropriate figure legend.
Surface plasmon resonance determinations
These experiments were performed with a Biacore X100 equipment (Biacore AB) at the Centro de Investigaciones Biológicas facility. GST-CSH3
WT protein was immobilized onto a sensor chip CM5 (GE Healthcare) through the amine coupling procedure according to the supplier's instructions. Experiments were performed in HBS-EP running buffer [0.01 M Hepes (pH 7.4), 150 mM NaCl, 3 mM EDTA, 0.005% (v/v) surfactant P20]. MBPs (100 mM) were dialyzed overnight in running buffer without surfactant and then were injected at a flow rate of 30 ml/min through both GST-CSH3 WT -containing and non-protein-containing (control) cells. Dissociation was performed in HBS-EP running buffer. For graphical representation, raw data were imported into Prism 5 (GraphPad) and plotted. When required, regeneration of the cell chip was performed with an injection of 50 mM NaOH for 30 s.
EM analysis and 3D reconstruction
A 6xHis-tagged version of the Vav1 D1-144 mutant protein was expressed in insect Sf 9 cells and purified by metal affinity chromatography, as described previously (6, 7) . Eluates were subjected to size exclusion chromatography with a Superdex 200 PC3.2/30 column (GE Healthcare) equilibrated in 50 mM tris-HCl (pH 7.5), 100 mM NaCl, 1 mM MgCl 2 , 1 mM DTT, and 10% glycerol. Aliquots of fractions obtained were analyzed by SDS-PAGE and silver-stained or, alternatively, were adsorbed on carbon-coated grids, stained with 2% (w/v) uranyl formate (Sigma), and analyzed in a JEOL 1230 transmission electron microscope operated at 100 kV. EM images were collected with a low-dose protocol and a 4k × 4k TVIPS complementary metal oxide semiconductor (CMOS) detector under the control of EM-TOOLS software (TVIPS). Final magnification of the CMOS micrographs was ×68,222, which were then down-sampled to a final 4.56 Å per pixel. The contrast transfer function for each micrograph was estimated with CTFFIND3 (contrast transfer function and FIND 3) (62) and corrected with Bsoft (Bernard's Software) (63) . A total of 4970 images of individual molecules were selected from micrographs and processed with EMAN (electron microscopy analysis) (64) . Reference-free averages were obtained from XMIPP (X-Window-based Microscopy Image Processing Package). The structure was obtained by angular refinement methods as implemented in EMAN (64) and with several templates for refinement, including different random noisy Gaussian blobs, which converged to the same solution. The resolution of the structures was estimated as 32.5 Å by Fourier shell correlation and a 0.5 correlation coefficient.
Structural modeling
Visualization of protein structures was performed with MacPyMOL software (version 1.5, DeLano Scientific LLC). Protein data bank (PDB) files for Vav1 CH-Ac-DH-PH-ZF (3KY9), Vav1 DH-PH-ZF (2VRW), and Vav CSH3 (2DM1 and 2KBT) were retrieved from the Research Collaboratory for Structural Bioinformatics (RCSB) PDB. The structure of the Vav1 CSH3 domain was modeled bioinformatically from the PDB 2DM1 file with Phyre2 software (http://www.sbg.bio.ic.ac.uk/phyre2) (65).
Phospho-site determinations
Vav1 immunoprecipitates obtained from unstimulated and EGF-stimulated COS1 cells and from unstimulated and anti-CD3-stimulated Jurkat cells were separated electrophoretically and stained with imidazole and zinc. Bands corresponding to Vav1 were cut from the gel, trypsinized, and analyzed with a LCQ DECA XP mass spectrophotometer apparatus (Thermo Finnigan). Phospho-sites detected in three independent determinations were used for further characterization. In addition to the sites described in this work, we also detected that Tyr 725 of Vav1 was phosphorylated only in the case of EGF-stimulated COS1 cells. We have also identified a number of serine and threonine residues that were not characterized in this study. To confirm the phosphorylation of those sites using independent techniques, we analyzed their phosphorylation status in Vav1 immunoprecipitates obtained from Jurkat cells that were subjected to Western blotting analyses with phospho-specific antibodies. After this step, blots were stripped and then incubated with antibodies specific for Vav1.
Image processing
All images and figures were assembled and processed for final presentation with Canvas 12 software (Deneba Systems).
Statistical analyses
Where indicated, the Mann-Whitney U test was applied to the data using, as a minimum, three independent experiments, each of which was performed with triplicate samples. *P ≤ 0.05, **P ≤ 0.01, and ***P ≤ 0.001. In all figures, data values and error bars are given as means ± SEM.
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